Literature DB >> 34162934

Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan.

Shigeru Honda1, Yasuo Yanagi2, Hideki Koizumi3, Yirong Chen4, Satoru Tanaka5, Manami Arimoto6, Kota Imai5.   

Abstract

The chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using data from the Japan National Health and Wellness surveys 2009-2014. Out of 147,272 respondents, 100 nAMD patients reported currently receiving treatment. Controls without nAMD were selected by 1:4 propensity score matching. Healthcare Resource Utilisation (HRU), Health-Related Quality of Life (HRQoL), and work productivity loss were compared between the groups. Regarding HRU, nAMD patients had significantly increased number of visits to any healthcare provider (HCP) (13.8 vs. 8.2), ophthalmologist (5.6 vs. 0.8), and other HCP (9.5 vs. 7.1) compared to controls after adjusting for confounding factors. Additionally, nAMD patients had reduced HRQoL and work productivity, i.e., reduced physical component summary (PCS) score (46.3 vs. 47.9), increased absenteeism (18.14% vs. 0.24%), presenteeism (23.89% vs. 12.44%), and total work productivity impairment (33.57% vs. 16.24%). The increased number of ophthalmologist visits were associated with decreased PCS score, increased presenteeism and total work productivity impairment. The current study highlighted substantial burden for nAMD patients, requiring further attention for future healthcare planning and treatment development.

Entities:  

Year:  2021        PMID: 34162934     DOI: 10.1038/s41598-021-92567-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  3 in total

1.  Health resource utilization and the economic burden of patients with wet age-related macular degeneration in Thailand.

Authors:  Piyameth Dilokthornsakul; Nathorn Chaiyakunapruk; Paisan Ruamviboonsuk; Mansing Ratanasukon; Somsanguan Ausayakhun; Akrapope Tungsomeroengwong; Nattapol Pokawattana; Chalakorn Chanatittarat
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

2.  [Treatment guidelines for age-related macular degeneration].

Authors:  Kanji Takahashi; Yuichiro Ogura; Tatsuro Ishibashi; Fumio Shiraga; Mitsuko Yuzawa
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2012-12

Review 3.  Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations.

Authors:  Laurent Kodjikian; Mariacristina Parravano; Andreas Clemens; Rosa Dolz-Marco; Frank G Holz; Marion R Munk; Massimo Nicolò; Federico Ricci; Rufino Silva; S James Talks; Rohini Kumar Verma; Javier Zarranz-Ventura; Sandrine A Zweifel
Journal:  Eye (Lond)       Date:  2021-04-01       Impact factor: 3.775

  3 in total
  1 in total

Review 1.  Effectiveness of Current Treatments for Wet Age-Related Macular Degeneration in Japan: A Systematic Review and Pooled Data Analysis.

Authors:  Kanji Takahashi; Tomohiro Iida; Susumu Ishida; Bruce Crawford; Yoko Sakai; Akikazu Mochizuki; Ryuta Tsujiuchi; Satoru Tanaka; Kota Imai
Journal:  Clin Ophthalmol       Date:  2022-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.